We report on a currently 76-year-old female patient with relapsed/refractory (RR) multiple myeloma (MM) treated at our institution. This patient had received six lines of therapy including tandem autologous stem cell transplant, proteasome inhibitor, immunomodulatory drugs and CD38 antibody MOR202. At the last relapse, she progressed during treatment with pomalidomide and MOR202. In an individualized therapy concept, we started a multi-agent salvage therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and CD38 antibody daratumumab (“Pom-PAD-Dara”), which resulted in a stringent complete remission with minimal residual disease (MRD) negativity after nine cycles. So far, our patient shows a progression free survival of more than 12 months. Our case demonstrates the feasibility of successful CD38 antibody retreatment in a patient with heavily pretreated CD38 antibody resistant MM.

我们报告了一名目前在我们机构接受治疗的 76 岁女性复发/难治性 (RR) 多发性骨髓瘤 (MM) 患者。该患者接受了六线治疗，包括串联自体干细胞移植、蛋白酶体抑制剂、免疫调节药物和CD38抗体MOR202。在最后一次复发时，她在接受泊马度胺和 MOR202 治疗期间出现进展。在个体化治疗概念中，我们开始使用泊马度胺、硼替佐米、多柔比星、地塞米松和 CD38 抗体达雷妥尤单抗 (“Pom-PAD-Dara”) 进行多药补救治疗，从而实现了具有微小残留病灶 (MRD) 的严格完全缓解) 九个循环后为负。到目前为止，我们的患者显示出超过 12 个月的无进展生存期。